Personalized immune cell therapy for HPV-related advanced cancer
Treatments studied
Part of Cancer, Digestive system, Ear, nose & throat, Kidney & urinary, Mouth & dental, Women’s health & pregnancy clinical trials.
This study tests a new treatment using your own immune cells (called SCG142) that are specially trained to attack cancer cells linked to HPV 16 or 52. It may help people with advanced squamous cell cancers who have not gotten better with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of cancer called squamous cell carcinoma of the cervix, head and neck, anus, penis, vulva, or vagina.
- Your tumor tests positive for HPV type 16 or 52.
- You have the HLA-A*02:01 genetic marker (a blood test checks this).
- Your cancer is advanced or has spread, and you have already tried at least one standard treatment.
- You are generally able to care for yourself (ECOG performance status 0 or 1) and have a life expectancy of at least 3 months.
- You do not have serious heart, lung, brain, or immune system conditions, and you have not had an organ transplant or prior cell therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of immune cell therapy for advanced throat cancer tied to HPV infection. Your own immune cells are reprogrammed in a lab to better attack cancer cells, then given back to you. It aims to help people whose cancer has not responded to standard treatments.
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
This trial compares a personalized, shorter course of radiation therapy to the standard longer course for people with HPV-positive throat cancer. The goal is to see if personalized treatment is just as effective while reducing side effects.
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
This trial tests a new treatment called SCG142 TCR-T cells for cancers caused by HPV. The therapy uses your own immune cells to fight the tumor. It may help if other treatments haven't worked or are not available.
Hear when a new HPV-Related Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.